» Articles » PMID: 34733959

Safflower Yellow Pigment and Sanqi in the Treatment of Acute Cerebral Infarction: a Systematic Review, Meta-analysis, and Cost-effectiveness Analysis

Overview
Journal Ann Transl Med
Date 2021 Nov 4
PMID 34733959
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sanqi injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze the published reports of efficacy and safety of Sanqi injection and safflower yellow injection for the treatment of acute cerebral infarction. The cost-effectiveness of these drug formulations was also evaluated.

Methods: China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, and the Chinese Biomedical Literature (CBM) were searched with the restrictions keywords in Chinese and English between 2006 and 2019 to obtain RCTs. A meta-analysis and a meta-regression analysis were undertaken in Reviewer Manager 5.3 software to compare the efficacy and safety of Sanqi and safflower yellow injection. This study used a decision tree model to analyze the cost-effectiveness of the two treatments. The TreeAge Pro software was used to comprehensively evaluate the economics of these medications.

Results: Twelve papers were all randomized controlled trials (RCTs) in which Sanqi injection was applied in the control group, while safflower yellow injection was applied in the experimental group and the quality of them were good. The results of the 12 papers were compared, and the total effective rate of the treatment group (91.18%) was significant and showed no significant difference with the control group (74.83%) (RR =1.24, 95% CI: 1.19, 1.30, P<0.00001). From the perspective of pharmacoeconomics, compared with Sanqi group, the ICER of safflower yellow injection is 3,885.75 RMB. The sensitivity analysis results were consistent with the basic analysis results, indicating that the basic analysis results were relatively stable.

Conclusions: Comparing with Sanqi injection, safflower yellow injection and related combination therapy can improve the total effective rate and are safer with fewer adverse reactions. It is also more cost-effective than the use of Sanqi injection.

Citing Articles

Clinical characteristics of heavy alcohol consumption in young and middle-aged acute cerebral infarction: A 12-month follow-up study.

Liao J, Li X, Wang L, Chen M, Quan F, Xi Z Heliyon. 2024; 10(9):e30416.

PMID: 38726157 PMC: 11079088. DOI: 10.1016/j.heliyon.2024.e30416.

References
1.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

2.
Li L, Li Y, Qiao B, Jiang S, Li X, Du H . The Value of Safflower Yellow Injection for the Treatment of Acute Cerebral Infarction: A Randomized Controlled Trial. Evid Based Complement Alternat Med. 2015; 2015:478793. PMC: 4449919. DOI: 10.1155/2015/478793. View

3.
Peng X, Yan L, Liu C, Wang S, Li W, Gao X . Benign disease prone to be misdiagnosed as malignant pulmonary nodules: Minute meningothelioid nodules. Thorac Cancer. 2019; 10(5):1182-1187. PMC: 6501004. DOI: 10.1111/1759-7714.13061. View

4.
Goodyear M, Krleza-Jeric K, Lemmens T . The Declaration of Helsinki. BMJ. 2007; 335(7621):624-5. PMC: 1995496. DOI: 10.1136/bmj.39339.610000.BE. View

5.
Du S, Deng Y, Yuan H, Sun Y . Safflower Yellow B Protects Brain against Cerebral Ischemia Reperfusion Injury through AMPK/NF-kB Pathway. Evid Based Complement Alternat Med. 2019; 2019:7219740. PMC: 6378026. DOI: 10.1155/2019/7219740. View